AI Article Synopsis
- The study combines Prussian Blue nanoparticles (PBNPs) with αCD137 antibodies to create a new anti-tumor treatment platform for melanoma.
- These αCD137-PBNPs maintain their therapeutic properties and were tested for effectiveness and safety in mice with tumors.
- Results showed that mice treated with the αCD137-PBNP-PTT had a much better survival rate (50%) and no liver toxicity compared to other treatments.
Article Abstract
We investigate combining Prussian Blue nanoparticles (PBNPs), as photothermal therapy (PTT) agents, with agonistic CD137 antibodies (αCD137) on a single nanoparticle platform to deliver non-toxic, anti-tumor efficacy in SM1 murine melanoma. We electrostatically coated PBNPs with αCD137 (αCD137-PBNPs) and quantified their physicochemical characteristics, photothermal and co-stimulatory capabilities. Next, we tested the efficacy and hepatotoxicity of PTT using αCD137-PBNPs (αCD137-PBNP-PTT) in SM1 tumor-bearing mice. The αCD137-PBNPs retained both the photothermal and agonistic properties of the PBNPs and αCD137, respectively. , SM1 tumor-bearing mice treated with αCD137-PBNP-PTT exhibited a significantly higher survival rate (50%) without hepatotoxicity, compared with control treatments. These data suggest the potential utility of co-localizing PBNP-PTT with αCD137-based agonism as a novel combination nanomedicine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485692 | PMC |
| http://dx.doi.org/10.1080/17435889.2024.2389770 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!